Last reviewed · How we verify

Darunavir/Ritonavir (Prezista)

Kowa Research Institute, Inc. · FDA-approved active Small molecule

Darunavir/Ritonavir (Prezista) is a HIV protease inhibitor Small molecule drug developed by Kowa Research Institute, Inc.. It is currently FDA-approved for HIV-1 infection in treatment-experienced patients, HIV-1 infection in treatment-naïve patients.

Darunavir is an HIV protease inhibitor that blocks the viral protease enzyme, preventing the maturation of HIV particles and reducing viral replication.

Darunavir is an HIV protease inhibitor that blocks the viral protease enzyme, preventing the maturation of HIV particles and reducing viral replication. Used for HIV-1 infection in treatment-experienced patients, HIV-1 infection in treatment-naïve patients.

At a glance

Generic nameDarunavir/Ritonavir (Prezista)
SponsorKowa Research Institute, Inc.
Drug classHIV protease inhibitor
TargetHIV protease
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Darunavir binds to the HIV protease active site with high affinity, inhibiting the cleavage of viral polyproteins into functional enzymes and structural proteins. This prevents the formation of mature, infectious viral particles. Ritonavir is a pharmacokinetic booster that inhibits cytochrome P450 metabolism, increasing darunavir plasma concentrations and half-life.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Darunavir/Ritonavir (Prezista)

What is Darunavir/Ritonavir (Prezista)?

Darunavir/Ritonavir (Prezista) is a HIV protease inhibitor drug developed by Kowa Research Institute, Inc., indicated for HIV-1 infection in treatment-experienced patients, HIV-1 infection in treatment-naïve patients.

How does Darunavir/Ritonavir (Prezista) work?

Darunavir is an HIV protease inhibitor that blocks the viral protease enzyme, preventing the maturation of HIV particles and reducing viral replication.

What is Darunavir/Ritonavir (Prezista) used for?

Darunavir/Ritonavir (Prezista) is indicated for HIV-1 infection in treatment-experienced patients, HIV-1 infection in treatment-naïve patients.

Who makes Darunavir/Ritonavir (Prezista)?

Darunavir/Ritonavir (Prezista) is developed and marketed by Kowa Research Institute, Inc. (see full Kowa Research Institute, Inc. pipeline at /company/kowa-research-institute-inc).

What drug class is Darunavir/Ritonavir (Prezista) in?

Darunavir/Ritonavir (Prezista) belongs to the HIV protease inhibitor class. See all HIV protease inhibitor drugs at /class/hiv-protease-inhibitor.

What development phase is Darunavir/Ritonavir (Prezista) in?

Darunavir/Ritonavir (Prezista) is FDA-approved (marketed).

What are the side effects of Darunavir/Ritonavir (Prezista)?

Common side effects of Darunavir/Ritonavir (Prezista) include Diarrhea, Nausea, Headache, Rash, Abdominal pain, Vomiting.

What does Darunavir/Ritonavir (Prezista) target?

Darunavir/Ritonavir (Prezista) targets HIV protease and is a HIV protease inhibitor.

Related